Is cerebrospinal fluid amyloid‐β42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients?

INTRODUCTION: Nusinersen was approved as the first treatment for all types of spinal muscular atrophy (SMA), including adults with SMA types 2 and 3. Robust biomarkers of treatment response in SMA adults are lacking. Our aim was to examine cerebrospinal fluid (CSF) amyloid‐β40 (Aβ40) and amyloid‐β42...

Descripción completa

Detalles Bibliográficos
Autores principales: Introna, Alessandro, Milella, Giammarco, D'Errico, Eustachio, Fraddosio, Angela, Scaglione, Gaspare, Ucci, Maria, Ruggieri, Maddalena, Simone, Isabella Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Clinical Research Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251706/
https://www.ncbi.nlm.nih.gov/pubmed/33660868
http://dx.doi.org/10.1002/mus.27212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251706/
https://www.ncbi.nlm.nih.gov/pubmed/33660868
http://dx.doi.org/10.1002/mus.27212

Ejemplares similares